BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37269147)

  • 1. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
    Pai SM; Yamada H; Murata H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
    Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
    J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
    Koo SH; Soon GH; Pruvost A; Benech H; Ang TL; Lee EJD; Ang DSW
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jul; 395(7):815-826. PubMed ID: 35394133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
    Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
    Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
    Ermer J; Corcoran M; Martin P
    Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
    Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
    Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
    Tran JQ; Othman AA; Wolstencroft P; Elkins J
    Br J Clin Pharmacol; 2016 Jul; 82(1):160-7. PubMed ID: 26991517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
    Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y
    Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers.
    Doroshyenko O; Rokitta D; Zadoyan G; Klement S; Schläfke S; Dienel A; Gramatté T; Lück H; Fuhr U
    Drug Metab Dispos; 2013 May; 41(5):987-93. PubMed ID: 23401474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
    Murase K; Lee L; Ma J; Barrett R; Thoolen M
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1823-1831. PubMed ID: 36166059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats.
    Zhang S; Song N; Li Q; Fan H; Liu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):78-89. PubMed ID: 18614408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.